Mode
Text Size
Log in / Sign up

Genetic prevalence estimates for 22 autosomal recessive conditions show wide carrier frequency rangeHow common are rare genetic conditions? New tool gives clearer estimates

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note: Genetic prevalence estimates are dynamic measures based on evolving population databases.

This analysis used population data from the Genome Aggregation Database (gnomAD) to estimate genetic prevalence for 22 autosomal recessive conditions. The work was conducted in partnership with 18 Rare As One patient organizations and involved the development of a Genetic Prevalence Estimator (GeniE) tool. The study type, phase, and specific sample size were not reported.

The main results showed conservative carrier frequencies ranging from 1/164 to 1/11,888 across the conditions studied. The median change in genetic prevalence frequency between gnomAD version 2.1 and version 4.1 was 0.806. Specific effect sizes, absolute numbers, and statistical confidence intervals for these estimates were not reported.

Safety and tolerability data were not applicable to this population data analysis. Key limitations, including potential biases in the underlying genomic database or methodological constraints of the estimator tool, were not detailed in the provided information. Funding sources and conflicts of interest were also not reported.

The practice relevance of this work lies in providing updated carrier frequency estimates, which can inform population genetics and rare disease understanding. However, clinicians should recognize that genetic prevalence is not a static figure but a dynamic, evolving measure with important caveats, necessitating re-evaluations as genomic databases expand. The findings are descriptive and do not establish clinical outcomes.

If you're planning a family, you might wonder about the chances of passing on a rare genetic condition. A new project, built in partnership with 18 rare disease patient organizations, tried to get clearer answers for 22 specific conditions. They developed a tool called the Genetic Prevalence Estimator (GeniE) to analyze population genetic data from a large public database.

The analysis found that the estimated chance of being a carrier—meaning you have one copy of a gene linked to a recessive condition—varied a lot. For the conditions they studied, the conservative estimates ranged from about 1 in 164 people to 1 in nearly 12,000 people. The study also showed that these estimates aren't fixed; when they compared two versions of the genetic database, the median change in the calculated frequency was about 0.8, meaning the numbers shifted.

This work is important because it gives patient communities and researchers a more grounded starting point for understanding how many people might be affected. However, the key takeaway is that genetic prevalence is a moving target. The numbers are based on the data available today and will need to be re-evaluated as genetic databases grow and become more diverse. This tool offers a clearer picture for now, but it's a picture that's still developing.

What this means for you:
Estimates of how many people carry genes for rare diseases are improving, but they're not final numbers.

Study Details

EvidenceLevel 5
PublishedMar 2026
View Original Abstract ↓
Introduction: Accurate estimation of disease prevalence is crucial for public health and therapeutic development, but traditional methods are often inaccurate. Genetic prevalence, which estimates the proportion of a population with a causal genotype, using allele frequencies from population data, offers an important alternative. Methods: We partnered with 18 Rare As One patient organizations to estimate genetic prevalence for 22 autosomal recessive conditions using population data from two releases of the Genome Aggregation Database (gnomAD). To standardize and democratize these analyses, we developed the Genetic Prevalence Estimator (GeniE), a publicly available tool, for accessible calculations. Results: Conservative carrier frequencies in gnomAD v4.1 ranged from 1/164 to 1/11,888. The median change in genetic prevalence frequency between v2.1 to v4.1 was 0.806. Partnership with patient advocacy groups provided critical real-world context that refined the interpretation of these estimates. Discussion: These findings highlight that genetic prevalence is not a static figure but a dynamic, evolving measure with important caveats that need to be considered. Our study underscores the necessity of re-evaluations as databases expand. By integrating patient-partnered insights with the GeniE platform, we empower the genomics community to maintain transparent, up-to-date, and actionable data for rare disease advocacy and drug development.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.